Discussion
The pooled prevalence estimate for perinatal PTSD in LMIC settings was 4.2% for clinically diagnosed PTSD and 11.0% for self-reported symptoms of PTSD. These findings suggest that perinatal PTSD represents a significant burden within LMIC settings, with approximately 1 in 10 perinatal women experiencing PTSD symptoms and 1 in 20 perinatal women having a clinical diagnosis of PTSD. The prevalence of PTSD was similar in the antenatal and postnatal periods: the prevalence of clinically diagnosed PTSD was 4.1% antenatally and 5.4% postnatally, and the prevalence of self-reported symptoms of PTSD was 9.6% antenatally and 11.6% postnatally. However, high levels of statistical heterogeneity in the meta-analyses means these pooled estimates must be interpreted with caution.
Our estimates are not directly comparable with those of Yildiz et al
14 due to differences in inclusion criteria and synthesis of results. Yildiz et al report a prevalence of PTSD using diagnostic measures (defined in their review as clinical interviews or self-report measures that use DSM diagnostic criteria) among community-based samples from predominantly HICs of 3.3% antenatally and 4.0% post partum: these estimates are in line with our estimates of clinically diagnosed PTSD of 4.1% and 5.4%, respectively.
The difference in estimates of clinically diagnosed PTSD compared with self-reported PTSD symptoms is unsurprising given that not all those with self-reported symptoms will meet the criteria for a clinical diagnosis. The magnitude of the difference (4.2% vs 11.0%) highlights the importance of distinguishing between the two—a distinction that is not always clear in reported estimates. Antenatal and postnatal prevalence estimates were similar, reflecting findings of a previous review.14 There was some evidence of differences in pooled prevalence across geographical regions, with lower prevalence in South Asia compared with other regions. Authors of a recent review of adolescent perinatal mental health in South Asia and sub-Saharan Africa called for more research to understand local conceptualisations of mental health and trauma.75 Studies from the East and Central Asia and Africa were limited and all but one of the studies from Latin America were conducted in Brazil, with differences in estimates seen even among studies from this single country.
Statistical heterogeneity persisted in subgroup analyses, and individual studies reported a wide variation in prevalence estimates ranging from 0% to over 50%. This variation may be explained by a number of possible factors. First, different self-report measures were used across studies, and although all measures were reported as having been validated, there may have been variation in the quality of translation and cultural adaptation of measures across studies. There is important emerging evidence of cross-cultural variability in the salience of avoidance or numbing symptoms and in the prevalence of somatic symptoms, suggesting that that ‘Western-centric’ diagnostic criteria may be less effective in detecting PTSD in LMIC contexts.76 Robust local validation of measures is therefore crucial as to avoid underdetection of PTSD. Second, the mode of administration of assessments—for example, whether self-report measures are read out loud by a healthcare worker or study team member or self-completed by respondents—may influence reported prevalence. Third, characteristics of study populations may have differed across studies. For example, studies which recruited participants from hospital settings may have included higher risk individuals than those recruiting from community-based settings. Finally, the use of LMIC as a category has received criticism for being overly broad and perpetuating unwarranted divisions between countries.77 The 163 countries currently classified as LMIC are highly diverse in terms of their populations, cultures and health infrastructure, and the variation in prevalence across studies may reflect some of these underlying differences.
Two-thirds of included studies were deemed to be at moderate or high risk of bias and this may have contributed further to variability in estimates. Although we found no evidence for statistically significant differences according to study quality, CIs and PIs were narrower for studies at low risk of bias. This suggests that we might have more confidence in pooled prevalence estimates of 8.0% for self-reported PTSD symptoms and 3.8% for clinically diagnosed PTSD generated from analyses limited to low risk of bias studies only.
There were a number of notable outliers. Ayu et al assessed PTSD prevalence among pregnant women in Indonesia and reported a PTSD prevalence of 41%. Almost half of participants included in this study were adolescents, who may face greater risks compared with adult perinatal populations.29 Türkmen et al assessed PTSD among postnatal women in the Republic of Türkiye and found rates of 60%, 53% and 42% at 1, 3 and 6 months post partum, respectively.69 The authors acknowledged that their rates could not be generalised to the wider perinatal population in Türkiye and attributed this to their study being the first to use the Turkish PTSD Short Scale.69 Two Brazilian studies also reported high prevalence: Angelini et al’s study of postnatal women found a prevalence of self-reported PTSD symptoms of 49% using the PCL-Civilian version, while Osório et al found a prevalence of clinically diagnosed PTSD of 30% using a diagnostic interview.28 57 Osório et al suggest that their findings might be explained by high levels of previous mental disorders, obstetric complications and infant health conditions among their community sample.57
Strengths and limitations
This is the first systematic review to provide a pooled estimate of perinatal PTSD prevalence in LMICs.
The inclusion of PTSD symptoms as well as clinically diagnosed PTSD provides a comprehensive overview and recognises those who experience symptoms without meeting diagnostic criteria. The focus on community-based rather than high-risk samples means pooled estimates are likely to represent the general population of pregnant and postnatal women across LMICs. The review incorporates studies conducted before, during and after the COVID-19 pandemic and provides updated estimates. The majority of included studies were conducted after 2017 when the previous review was published. An extensive grey literature search which identified 12 additional studies and the inclusion of publications in any language represent further strengths.
There are also a number of limitations to the review. Statistical heterogeneity between studies was high (I2>90%) and remained significant in subgroup analyses. Meta-analyses of prevalence often have high I2 values but this is not always discriminative.78 Potential sources of heterogeneity were further explored using meta-regression and by assessing the impact on pooled estimates of using fixed-effects rather than random-effects meta-analysis. We recognise that excluding high-risk samples may be considered a limitation and that our results may underestimate the true burden of perinatal PTSD in LMICs. However, our rationale for focusing on general perinatal samples was that we wanted to understand the burden within—and the resulting resource implications for—general perinatal settings. High-risk groups exposed to specific trigger events are likely to follow different care pathways. Nevertheless, future studies should consider exploring higher risk groups. The lack of data on stressor events is a further limitation. We were unable to explore the difference in estimates between cohort studies and cross-sectional studies. This is important as the former allow more detailed insights into the incidence and evolution of PTSD and how prevalence might change over the perinatal period. Finally, the review was limited by a lack of studies from low-income (as opposed to middle-income) countries. Over two-thirds of included studies were from six countries, limiting the generalisability of findings across LMICs.
Implications for research and clinical practice
Currently, identification and treatment of women with perinatal PTSD is low in LMICs.79 Screening for PTSD symptoms during routine antenatal and postpartum appointments has been recommended to facilitate detection, though feasibility and effectiveness of such screening programmes will vary between settings and should be assessed according to local prevalence and existing mental health resources.9 Perinatal mental healthcare programmes including psychoeducational interventions that are integrated within antenatal and postpartum healthcare services have been shown to be effective.9 80–82 Research into perinatal PTSD in LMICs has increased as evidenced by the number of studies conducted within the last 5 years, yet significant gaps remain. Notably, studies from low-income (as opposed to middle-income) countries and certain geographical regions including East and Central Asia and North Africa are lacking. Reliable prevalence estimates from these settings are vital to better understand the burden and to inform health service planning.